A care & cost guide
What do the records actually say?
Separate approval, pharmacy rules and study findings. Each answers a different question about an offer of care.
Is there an approved product?
The US approval records checked September 28, 2026 contain no approved BPC-157 medicine for any use.
The US medicine regulator, the FDA (Food and Drug Administration), also reported that no country had approved a medicine containing it.
Check the basis for this answer
Evidence date: 28 September 2026.
What did the request to the FDA ask for?
Some groups asked the FDA to let pharmacies use raw BPC-157 to make medicines. Those groups took their requests back. On the FDA page marked current April 22, 2026, BPC-157 appears among these requests.
Taking back a request does not mean the FDA found BPC-157 safe or approved it. In the record checked September 28, 2026, the FDA continues to show safety concerns next to BPC-157.
The page also has a separate table for ingredients with safety concerns, called Category 2. BPC-157 is in the table of requests taken back, not that table. This difference does not remove the safety concerns.
The page does not give a date when the request was withdrawn.
Check the basis for this answer
Evidence date: 28 September 2026.
Can an ordinary pharmacy compound it?
Compounding means making a medicine for a patient. A bulk ingredient is the raw substance used to make it.
Raw BPC-157 does not meet the federal legal requirements for an ordinary pharmacy to use it in a made-to-order medicine. These rules were reviewed September 26, 2026.
BPC-157 has no entry setting quality requirements in the ingredient reference books named by this law.
No FDA-approved medicine contains it as an ingredient.
It is also missing from the official list of extra ingredients pharmacies may use.
Taking back the request to use BPC-157 does not change these legal requirements.
In July 2026, FDA staff argued against adding BPC-157 to the ingredient list.
A panel of experts met to advise the FDA about which ingredients pharmacies could use. But the Department of Health and Human Services (HHS) says in its October 30, 2026 draft that the July panel voted in favor of adding BPC-157.
The panel gives advice to the FDA. Its vote cannot add BPC-157 to the permitted ingredient list. The FDA must formally change the rule to add an ingredient, under the rules checked September 26, 2026.
Check the basis for this answer
The published federal rules have not changed, but HHS’s October 30, 2026 draft would hold off on enforcement. This concerns state-licensed pharmacies and licensed doctors preparing BPC-157 alone for one patient’s prescription if they meet the draft’s requirements. Withdrawing the request did not grant pharmacies permission to use this ingredient.
Evidence date: 17 September 2026.
Evidence date: 26 September 2026.
Evidence date: 28 September 2026.
Keep the questions separate
- ApprovalHas the regulator approved a finished medicine?
- CompoundingDoes the raw ingredient meet the pharmacy rules?
- EvidenceWhat has been shown in people?
How much human evidence is there?
In its review checked September 28, 2026, the FDA found five human studies, with fewer than a hundred people receiving BPC-157.
Two studies compared it with another treatment, but neither was published in full.
The small knee-pain and bladder reports did not compare people given BPC-157 with people who were not given it. They could not show whether BPC-157 caused people to feel better.
The FDA found too little information from people to judge BPC-157’s safety, in the review checked September 28, 2026.
These small reports can suggest what to study next. They cannot establish whether BPC-157 helps people or is safe for them.
Check the basis for this answer
Evidence date: 28 September 2026.